Scribe Therapeutics, Inc. — Form SCHEDULE 13D
Filed July 29, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC jointly filed a Schedule 13D on July 27, 2026, regarding common stock of Scribe Therapeutics Inc. The filing was executed July 29, 2026, with Carl L. Gordon signing on behalf of both entities. No specific stake percentage, share count, or acquisition price is disclosed in this joint filing agreement excerpt.
Why this rating
Schedule 13D is a routine 5% threshold disclosure; no dollar amounts, share counts, or stake details provided in excerpt. Cannot assess materiality without knowing company size or stake magnitude.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.